Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank82
3Y CAGR+39.2%
5Y CAGR+93.8%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+39.2%/yr
vs -29.2%/yr prior
5Y CAGR
+93.8%/yr
Recent deceleration
Acceleration
+68.4pp
Accelerating
Percentile
P82
Within normal range
vs 5Y Ago
27.4x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 213.82% |
| Q3 2025 | 62.56% |
| Q2 2025 | 316.19% |
| Q1 2025 | -118.26% |
| Q4 2024 | -17.03% |
| Q3 2024 | 572.82% |
| Q2 2024 | 183.06% |
| Q1 2024 | -110.47% |
| Q4 2023 | 23580.00% |
| Q3 2023 | -98.46% |
| Q2 2023 | 323.45% |
| Q1 2023 | -114.90% |
| Q4 2022 | 79.19% |
| Q3 2022 | 341.46% |
| Q2 2022 | 351.02% |
| Q1 2022 | -110.75% |
| Q4 2021 | -13.80% |
| Q3 2021 | 142.66% |
| Q2 2021 | 153.83% |
| Q1 2021 | -222.36% |
| Q4 2020 | 7.82% |
| Q3 2020 | 12.45% |
| Q2 2020 | -10.49% |
| Q1 2020 | -43.31% |
| Q4 2019 | 65.54% |
| Q3 2019 | 243.17% |
| Q2 2019 | -302.68% |
| Q1 2019 | -69.48% |
| Q4 2018 | -12.83% |
| Q3 2018 | 159.88% |
| Q2 2018 | -89.17% |
| Q1 2018 | 26.89% |
| Q4 2017 | 5.55% |
| Q3 2017 | 50.74% |
| Q2 2017 | 57.66% |
| Q1 2017 | -67.02% |
| Q4 2016 | -2.46% |
| Q3 2016 | 51.71% |
| Q2 2016 | -30.01% |
| Q1 2016 | -14.80% |